Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iSpecimen (ISPC) Depreciation & Amortization (CF): 2020-2025

Historic Depreciation & Amortization (CF) for iSpecimen (ISPC) over the last 6 years, with Sep 2025 value amounting to $457,730.

  • iSpecimen's Depreciation & Amortization (CF) fell 15.67% to $457,730 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 6.04%. This contributed to the annual value of $2.3 million for FY2024, which is 8.47% up from last year.
  • iSpecimen's Depreciation & Amortization (CF) amounted to $457,730 in Q3 2025, which was up 5.78% from $432,732 recorded in Q2 2025.
  • Over the past 5 years, iSpecimen's Depreciation & Amortization (CF) peaked at $606,744 during Q2 2024, and registered a low of $4,420 during Q2 2022.
  • Over the past 3 years, iSpecimen's median Depreciation & Amortization (CF) value was $432,732 (recorded in 2025), while the average stood at $339,542.
  • As far as peak fluctuations go, iSpecimen's Depreciation & Amortization (CF) plummeted by 60.29% in 2022, and later surged by 2,875.55% in 2024.
  • Quarterly analysis of 5 years shows iSpecimen's Depreciation & Amortization (CF) stood at $11,968 in 2021, then decreased by 26.09% to $8,846 in 2022, then surged by 108.21% to $18,418 in 2023, then soared by 2,875.55% to $548,036 in 2024, then decreased by 15.67% to $457,730 in 2025.
  • Its last three reported values are $457,730 in Q3 2025, $432,732 for Q2 2025, and $432,709 during Q1 2025.